Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: Comparison with CA 125 and the aminoterminal propeptide of type III procollagen

Antti Hakala, Barry M. Kacinski, E. Richard Stanley, Ernest I. Kohorn, Ulla Puistola, Juha Risteli, Leila Risteli, Candido Tomás, Antti Kauppila

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

OBJECTIVE: We investigated the clinical utility of macrophage colony- stimulating factor 1 versus CA 125 and the aminoterminal propeptide of type III procollagen in endometrial carcinoma. STUDY DESIGN: Serum levels of the three substances were measured in 159 patients with untreated endometrial adenocarcinoma and in 24 patients treated with cytotoxic chemotherapy for recurrent endometrial adenocarcinoma. RESULTS: Initial concentrations of colony-stimulating factor 1, CA 125, and the aminoterminal peptide of type III procollagen were above the normal range in 73%, 11%, and 27%, respectively, of the patients. Colony-stimulating factor 1 levels correlated with those of the aminoterminal peptide of type III procollagen (r = 0.3, p = 0.002) and CA 125 (r = 0.20, p = 0.036) in the total group and with those of the aminoterminal peptide of type III procollagen in stage I and II patients (r = 0.3, p = 0.0023). Colony-stimulating factor 1 levels correlated significantly with tumor grade, whereas those of CA 125 and the aminoterminal peptide of type III procollagen correlated more closely with clinical stage. Mean colony-stimulating factor 1 levels (9.6 vs 7.7 ng/ml, p = 0.04) and the frequency of elevated CA 125 levels (31% vs 8%, p = 0.048) were higher in patients with poor prognosis than in those with good prognosis. Colony- stimulating factor 1, the aminoterminal peptide of type III procollagen, and CA 125 levels were useful in monitoring clinical behavior of the disease in 88%, 79%, and 63% of the cases, respectively. Levels of all three markers rose with disease progression, whereas colony-stimulating factor 1 and the aminoterminal peptide of type III procollagen fell with clinical responses to therapy. CONCLUSION: Elevated serum colony-stimulating factor 1 levels were the most accurate indicator of the presence and activity (progression, stabilization, or regression) of primary or recurrent disease. Accuracy was not further enhanced by measurement of CA 125 or the aminoterminal peptide of type III procollagen levels.

Original languageEnglish (US)
Pages (from-to)112-119
Number of pages8
JournalAmerican Journal of Obstetrics and Gynecology
Volume173
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Macrophage Colony-Stimulating Factor
Collagen Type III
Tumor Biomarkers
Adenocarcinoma
Peptides
Endometrial Neoplasms
Serum
Disease Progression
Reference Values
Drug Therapy

Keywords

  • collagen metabolism
  • cytokines
  • Endometrial neoplasms
  • tumor antigens
  • tumor markers

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma : Comparison with CA 125 and the aminoterminal propeptide of type III procollagen. / Hakala, Antti; Kacinski, Barry M.; Stanley, E. Richard; Kohorn, Ernest I.; Puistola, Ulla; Risteli, Juha; Risteli, Leila; Tomás, Candido; Kauppila, Antti.

In: American Journal of Obstetrics and Gynecology, Vol. 173, No. 1, 1995, p. 112-119.

Research output: Contribution to journalArticle

Hakala, Antti ; Kacinski, Barry M. ; Stanley, E. Richard ; Kohorn, Ernest I. ; Puistola, Ulla ; Risteli, Juha ; Risteli, Leila ; Tomás, Candido ; Kauppila, Antti. / Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma : Comparison with CA 125 and the aminoterminal propeptide of type III procollagen. In: American Journal of Obstetrics and Gynecology. 1995 ; Vol. 173, No. 1. pp. 112-119.
@article{3d5adc7f9b5d41f590e32f64d45e88bf,
title = "Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: Comparison with CA 125 and the aminoterminal propeptide of type III procollagen",
abstract = "OBJECTIVE: We investigated the clinical utility of macrophage colony- stimulating factor 1 versus CA 125 and the aminoterminal propeptide of type III procollagen in endometrial carcinoma. STUDY DESIGN: Serum levels of the three substances were measured in 159 patients with untreated endometrial adenocarcinoma and in 24 patients treated with cytotoxic chemotherapy for recurrent endometrial adenocarcinoma. RESULTS: Initial concentrations of colony-stimulating factor 1, CA 125, and the aminoterminal peptide of type III procollagen were above the normal range in 73{\%}, 11{\%}, and 27{\%}, respectively, of the patients. Colony-stimulating factor 1 levels correlated with those of the aminoterminal peptide of type III procollagen (r = 0.3, p = 0.002) and CA 125 (r = 0.20, p = 0.036) in the total group and with those of the aminoterminal peptide of type III procollagen in stage I and II patients (r = 0.3, p = 0.0023). Colony-stimulating factor 1 levels correlated significantly with tumor grade, whereas those of CA 125 and the aminoterminal peptide of type III procollagen correlated more closely with clinical stage. Mean colony-stimulating factor 1 levels (9.6 vs 7.7 ng/ml, p = 0.04) and the frequency of elevated CA 125 levels (31{\%} vs 8{\%}, p = 0.048) were higher in patients with poor prognosis than in those with good prognosis. Colony- stimulating factor 1, the aminoterminal peptide of type III procollagen, and CA 125 levels were useful in monitoring clinical behavior of the disease in 88{\%}, 79{\%}, and 63{\%} of the cases, respectively. Levels of all three markers rose with disease progression, whereas colony-stimulating factor 1 and the aminoterminal peptide of type III procollagen fell with clinical responses to therapy. CONCLUSION: Elevated serum colony-stimulating factor 1 levels were the most accurate indicator of the presence and activity (progression, stabilization, or regression) of primary or recurrent disease. Accuracy was not further enhanced by measurement of CA 125 or the aminoterminal peptide of type III procollagen levels.",
keywords = "collagen metabolism, cytokines, Endometrial neoplasms, tumor antigens, tumor markers",
author = "Antti Hakala and Kacinski, {Barry M.} and Stanley, {E. Richard} and Kohorn, {Ernest I.} and Ulla Puistola and Juha Risteli and Leila Risteli and Candido Tom{\'a}s and Antti Kauppila",
year = "1995",
doi = "10.1016/0002-9378(95)90178-7",
language = "English (US)",
volume = "173",
pages = "112--119",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma

T2 - Comparison with CA 125 and the aminoterminal propeptide of type III procollagen

AU - Hakala, Antti

AU - Kacinski, Barry M.

AU - Stanley, E. Richard

AU - Kohorn, Ernest I.

AU - Puistola, Ulla

AU - Risteli, Juha

AU - Risteli, Leila

AU - Tomás, Candido

AU - Kauppila, Antti

PY - 1995

Y1 - 1995

N2 - OBJECTIVE: We investigated the clinical utility of macrophage colony- stimulating factor 1 versus CA 125 and the aminoterminal propeptide of type III procollagen in endometrial carcinoma. STUDY DESIGN: Serum levels of the three substances were measured in 159 patients with untreated endometrial adenocarcinoma and in 24 patients treated with cytotoxic chemotherapy for recurrent endometrial adenocarcinoma. RESULTS: Initial concentrations of colony-stimulating factor 1, CA 125, and the aminoterminal peptide of type III procollagen were above the normal range in 73%, 11%, and 27%, respectively, of the patients. Colony-stimulating factor 1 levels correlated with those of the aminoterminal peptide of type III procollagen (r = 0.3, p = 0.002) and CA 125 (r = 0.20, p = 0.036) in the total group and with those of the aminoterminal peptide of type III procollagen in stage I and II patients (r = 0.3, p = 0.0023). Colony-stimulating factor 1 levels correlated significantly with tumor grade, whereas those of CA 125 and the aminoterminal peptide of type III procollagen correlated more closely with clinical stage. Mean colony-stimulating factor 1 levels (9.6 vs 7.7 ng/ml, p = 0.04) and the frequency of elevated CA 125 levels (31% vs 8%, p = 0.048) were higher in patients with poor prognosis than in those with good prognosis. Colony- stimulating factor 1, the aminoterminal peptide of type III procollagen, and CA 125 levels were useful in monitoring clinical behavior of the disease in 88%, 79%, and 63% of the cases, respectively. Levels of all three markers rose with disease progression, whereas colony-stimulating factor 1 and the aminoterminal peptide of type III procollagen fell with clinical responses to therapy. CONCLUSION: Elevated serum colony-stimulating factor 1 levels were the most accurate indicator of the presence and activity (progression, stabilization, or regression) of primary or recurrent disease. Accuracy was not further enhanced by measurement of CA 125 or the aminoterminal peptide of type III procollagen levels.

AB - OBJECTIVE: We investigated the clinical utility of macrophage colony- stimulating factor 1 versus CA 125 and the aminoterminal propeptide of type III procollagen in endometrial carcinoma. STUDY DESIGN: Serum levels of the three substances were measured in 159 patients with untreated endometrial adenocarcinoma and in 24 patients treated with cytotoxic chemotherapy for recurrent endometrial adenocarcinoma. RESULTS: Initial concentrations of colony-stimulating factor 1, CA 125, and the aminoterminal peptide of type III procollagen were above the normal range in 73%, 11%, and 27%, respectively, of the patients. Colony-stimulating factor 1 levels correlated with those of the aminoterminal peptide of type III procollagen (r = 0.3, p = 0.002) and CA 125 (r = 0.20, p = 0.036) in the total group and with those of the aminoterminal peptide of type III procollagen in stage I and II patients (r = 0.3, p = 0.0023). Colony-stimulating factor 1 levels correlated significantly with tumor grade, whereas those of CA 125 and the aminoterminal peptide of type III procollagen correlated more closely with clinical stage. Mean colony-stimulating factor 1 levels (9.6 vs 7.7 ng/ml, p = 0.04) and the frequency of elevated CA 125 levels (31% vs 8%, p = 0.048) were higher in patients with poor prognosis than in those with good prognosis. Colony- stimulating factor 1, the aminoterminal peptide of type III procollagen, and CA 125 levels were useful in monitoring clinical behavior of the disease in 88%, 79%, and 63% of the cases, respectively. Levels of all three markers rose with disease progression, whereas colony-stimulating factor 1 and the aminoterminal peptide of type III procollagen fell with clinical responses to therapy. CONCLUSION: Elevated serum colony-stimulating factor 1 levels were the most accurate indicator of the presence and activity (progression, stabilization, or regression) of primary or recurrent disease. Accuracy was not further enhanced by measurement of CA 125 or the aminoterminal peptide of type III procollagen levels.

KW - collagen metabolism

KW - cytokines

KW - Endometrial neoplasms

KW - tumor antigens

KW - tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0029089423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029089423&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(95)90178-7

DO - 10.1016/0002-9378(95)90178-7

M3 - Article

C2 - 7631667

AN - SCOPUS:0029089423

VL - 173

SP - 112

EP - 119

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1

ER -